Free Biopharma Daily Stock Updates - 06/29/21

$XBI $135.7 -1.5%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$ALT -2.5% Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial. source

$ANGN +0.8% Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia. source

$MRNA +5.2% Moderna Announces Emergency Use Authorization for its COVID-19 Vaccine Granted by Government of India. source

$MRNA +5.2% Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India. source

$VBI -7.2% VBI Vaccines Announces Initial Positive Phase 1 Data for its eVLP Vaccine Candidate Against COVID-19. source

$RIGL -0.5% Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial. source

Pipeline Updates

$PTN +23.5% Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease. source

$MDWD -27.8% MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application. source

$VCEL -14.8% Vericel Provides Regulatory Update for NexoBrid. source

$TCON -1.7% TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma. source

$HRMY -0.7% Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy. source

$HZNP -1.0% Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus. source

$PRTK -1.3% Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA® (omadacycline) Valued at ~$38 Million. source

$OCUL -2.1% Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration. source

$CGEM -0.6% Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors. source

$ABUS -6.5% Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection. source

$ORTX -7.2% Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs. source

$TRIL -1.8% Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma. source

$DMAC -33.9% DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD. source

$IOVA -2.2% Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer. source

$CERE +136.2% Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia. source

$AVXL -18.1% on 6/28 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia. source

$SNSE -16.0% Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs. source

$XOMA +16.6% On 6/21 Declared Quarterly Preferred Stock Dividends. source

Financial Updates

$NTLA +13.6% On 6/28 Intellia Therapeutics Announces Proposed Public Offering of Common Stock. source

---

Posted by FS